Dutch multinational conglomerate Royal Philips Electronics, parent company of Philips Healthcare, and British medical technology company Biocompatibles have announced they will collaborate to advance the use of image guidance to control the delivery of beads during the arterial embolization of hypervascularized tumors.
The companies made the announcement on the eve of the annual meeting of the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) being held in Lisbon 15-19 September.
The first undertaking of the new collaboration will be the development of a new treatment protocol for transarterial embolization, a process demonstrated to reduce the size and rate of growth of tumors. The aim of the protocol is to standardize and optimize the current approach to treatment delivery, thereby ensuring the best possible patient outcome.
